Revised forecast
Fiscal year ending June 2026 · Full yearPrevious forecast published 8 August 2025 (full-year earnings forecast not disclosed)The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The forecast was previously not disclosed because it was difficult to reasonably forecast business expenses based on the progress of the CBP501 clinical trial, but the business expense outlook for the current fiscal year has now been calculated. Research and development expenses are expected to remain high due to regulatory and authority-related matters and preparations associated with the application to initiate CBP501's Phase 3 clinical trial in Europe, while business revenue from partnerships with pharmaceutical companies and others was not realized during the fiscal year.
| Item | Details |
|---|---|
| Operating profit | Not disclosed → ¥-1,258 million |
| Ordinary income | Not disclosed → ¥-1,220 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-1,222 million |
| Net income per share | Not disclosed → -62.02 yen and sen |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 August 2025 (full-year earnings forecast not disclosed) |
| Previous-period results | Business revenue –, operating profit –¥1,109 million, ordinary profit –¥1,156 million, net income –¥1,157 million, net income per share –¥61.14 |
| Reason for the revision | The forecast was previously not disclosed because it was difficult to reasonably forecast business expenses based on the progress of the CBP501 clinical trial, but the business expense outlook for the current fiscal year has now been calculated. Research and development expenses are expected to remain high due to regulatory and authority-related matters and preparations associated with the application to initiate CBP501's Phase 3 clinical trial in Europe, while business revenue from partnerships with pharmaceutical companies and others was not realized during the fiscal year. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses are expected to remain high due to regulatory and authority-related matters and preparations for the clinical trial associated with the application to initiate CBP501's Phase 3 clinical trial in Europe. In addition, income from partnerships with pharmaceutical companies and others was not realized during the fiscal year ending June 2026.